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vancomycin-resistant Enterococcus faecium:
case series and review of literature
Vincent CC Cheng1,2, Jonathan HK Chen1, Josepha WM Tai2, Sally CY Wong1, Rosana WS Poon1, Ivan FN Hung3,
Kelvin KW To1, Jasper FW Chan1, Pak-Leung Ho1, Chung-Mau Lo4 and Kwok-Yung Yuen1*Abstract
Background: Prolonged asymptomatic carriage of vancomycin-resistant enterococci (VRE) in the gastrointestinal
tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings.
Case presentation: We report a regimen for decolonization of gastrointestinal carriage of VRE by a combination of
environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using
polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any
remaining VRE, and subsequent oral Lactobacillus rhamnosus GG to maintain the colonization resistance in four
patients, including two patients with end-stage liver cirrhosis, one patient with complication post liver transplant,
and one patient with complicated infective endocarditis. All patients had clearance of VRE immediately after
decolonization, and 3 of them remained VRE-free for 23 to 137 days of hospitalization, despite subsequent use of
intravenous broad-spectrum antibiotics without anti-VRE activity.
Conclusion: This strategy should be further studied in settings of low VRE endemicity with limited isolation
facilities.
Keywords: Vancomycin-resistant enterococci, Decolonization, Bowel preparation, Polyethylene glycol, Linezolid,
Daptomycin, Lactobacillus rhamnosus GGBackground
Vancomycin-resistant enterococci (VRE) has been en-
demic in many parts of the word. Prolonged asympto-
matic carriage of VRE in the gastrointestinal tract and
the lack of effective decolonization regimen perpetuate
the endemicity of VRE in the healthcare settings [1]. In
Hong Kong, an increasing number of sporadic cases of
VRE are observed, with a prevalence of 0.32% of ad-
mission episodes by active surveillance culture [2]. We
adopted a proactive infection measures by the im-
plementation of active surveillance culture, extensive
contact tracing, isolation of VRE-positive patients and
environmental disinfection to control nosocomial trans-
mission of VRE [2-4]. However, the limited availability of* Correspondence: kyyuen@hkucc.hku.hk
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unless otherwise stated.single rooms fails to match with the increasing number of
patients colonized with VRE in recent years. Therefore, an
effective regimen for VRE decolonization is necessary in
resource-limited areas like Hong Kong. Here, we report a
protocol of VRE decolonization in four patients, including
two patients with end-stage liver cirrhosis awaiting liver
transplantation, one patient with a complicated post-liver
transplant recovery, and one patient with complicated in-
fective endocarditis. Decolonization of VRE is crucial in
liver transplant candidates as VRE colonization is associ-
ated with an increased risk of infection and death among
liver transplant recipients [5]. In contrast to the previous
attempt of VRE decolonization using only antimicrobial
agents or probiotics, we include the use of polyethylene
glycol for bowel preparation to wash-out the fecal
bacterial population prior to the administration of oral
linezolid and daptomycin. Lactobacillus rhamnosus GG is
then given to maintain the colonization resistance afterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2334/14/514antimicrobial decolonization. Our aim of VRE deco-
lonization was to reduce the risk of subsequent invasive
VRE infection among the high-risk patients, and to
limit the risk of nosocomial transmission of VRE in
our locality.
Case presentation
Decolonization of gastrointestinal carriage of VRE
Case 1: A 59-year-old man was referred to the Liver Trans-
plant Unit of Queen Mary Hospital, a university-affiliated
hospital with 1,600 bed, for consideration of cadaveric liver
transplantation due to chronic hepatitis B-related end-stage
cirrhosis on 14 September 2013. Queen Mary Hospital is
the only liver transplant center in Hong Kong, with
approximately 80 patients undergoing liver transplantation
per year. Upon admission, rectal swab with visible stool
content was collected for the detection of multidrug-
resistant organisms including VRE in accordance to the
hospital infection control policy. Briefly, patients with
history of hospitalization or receiving surgical operation
outside Hong Kong within the past 12 months before
admission or patients with history of admissions to other
local hospitals within the past 3 months were included in
the active surveillance [2,4,6]. The patient was confirmed to
be positive for vancomycin-resistant Enterococcus faecium
which was resistant to ampicillin, chloramphenicol, nitro-
furantoin, levofloxacin, minocycline, rifampicin, tetracyc-
line, fosfomycin, high-level gentamicin, and high-level
streptomycin. The minimal inhibitory concentration (MIC)
of vancomycin was >256 μg/ml. VanA gene was detected
by polymerase chain reaction (PCR). The MIC of linezolid
and daptomycin was 1.5 μg/ml and 3.0 μg/ml respectively,
while the MIC breakpoint of linezolid and daptomycin
was ≤ 2 μg/ml and ≤ 4 μg/ml for enterococcus species
respectively with reference to Clinical and Laboratory
Standards Institute. Multilocus sequence typing (MLST)Table 1 Protocol of vancomycin-resistant enterococci decolon
1. Patient was managed in isolation room A and subjected to bowel prepar
examination: (i) ingestion of 2 liters of polyethylene glycol (Klean prep) ov
rice water, clear soup, and fruit juice on the first day of decolonization.
2. When the defecated bowel content became clear fluid, patient was trans
with sodium hypochlorite 1,000 ppm.
3. After transferal to isolation room B, a five-day course of medication with
12 hourly, orally-taken intravenous preparation of daptomycin 8 mg per k
4. At the same time, the patient was cleansed with 4% chlorhexidine bath a
avoid use of other antibiotics treatment during the decolonization period
5. At the time of bathing, the patient’s clothes, underwear, and bed linens w
were disinfected to prevent re-colonization. The isolation room was thoro
twice daily.
6. After completion of 5-day decolonization regimen, Lactobacillus rhamnos
7. All foods and drinks throughout the decolonization procedure must be b
with alcohol based hand rub.
Note. VRE, vancomycin-resistant enterococci; *The decolonization protocol was desi
Mary Hospital. Infection control nurses closely monitored and audited the compliandemonstrated that the strain was ST761 (profile 70-1-1-1-
12-1-1), which is a member of the pandemic clonal com-
plex 17 lineage. The patient was isolated in a single room
with strict contact precautions since day 2 of
hospitalization. Healthcare workers wore gloves and gowns
during patient care practice. Alcohol-based hand rub was
provided in the isolation room for hand hygiene. Dedicated
medical items such as stethoscope, thermometer, and blood
pressure cuff were available and solely used on this patient.
Decolonization of VRE was performed between day 11 and
15 of hospitalization according to our protocol (Table 1).
The bacterial load of VRE in rectal swabs with visible stool
content was monitored daily. The VRE counts decreased
from >2×105 colony forming units per gram (cfu/g) of stool
(baseline on day 11) to 3.4×104 cfu/g of stool on day 12 and
undetectable (<200 cfu/g) on day 13. Despite the adminis-
tration of broad-spectrum antibiotics after successful
decolonization, the serial rectal swabs remained negative
for VRE in vancomycin and clindamycin containing entero-
coccal enrichment broth culture (Figure 1). ABO blood
group matched-cadaveric liver graft became available on
day 30 of hospitalization and transplantation was per-
formed under coverage with intravenous linezolid 600 mg
30 minutes before surgical incision, and one dose postoper-
atively. The operation lasted for 11 hours without immedi-
ate complications. Patient was managed in the adult
intensive care unit during the postoperative period and
transferred to the liver transplant ward on day 32 of
hospitalization (post-operative day 2). Serial rectal swabs
were collected on day 1, 3, 4, 5, 7, 10, 12, 14, and 17 after
liver transplantation, thereafter twice weekly until day 66,
and weekly until day 107 after liver transplantation (day
137 of hospitalization) (Figure 1). No growth of VRE was
detected in broth enrichment culture.
Case 2: A 56-year-old man had living-donor liver trans-
plantation for early stage of moderately differentiatedization*
ation according to the protocol commonly used prior to colonoscopy
er 6 hours to wash out the bowel content; (ii) taking fluid diet including
ferred from isolation room A to B, which had been terminally disinfected
activity against VRE was given, including oral linezolid 600 mg every
g daily.
nd shampoo, and oral chlorhexidine gargle for 5 days. Where possible,
.
ere replaced and sent for hot laundry daily. All personal belongings
ughly cleaned and disinfected by sodium hypochlorite 1,000 ppm
us GG 80 mg was given daily to replace the gut flora.
oiled. All visitors and healthcare workers must comply with hand hygiene
gned and coordinated by the infection control team for all patients in Queen
ce of the procedures required for decolonization.
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Figure 1 Serial quantitative culture of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium and concomitant use of
antimicrobial agents in case 1. Note. Intravenous meropenem 500 mg every 8 hourly was given between day 16 and 31 for recurrent isolation
of extended-spectrum β-lactamase-producing Klebsiella species in sputum; intravenous meropenem 500 mg every 8 hourly was given again
between day 41 and 49 for low grade fever without microbiological documentation of infection; oral levofloxacin 750 mg daily was given
between day 71 and 78 for urine isolation of extended-spectrum β-lactamase-producing Klebsiella species; oral cotrimoxazole 480 mg twice daily
was given after liver transplantation as pre-emptive prophylactic agent. The dotted horizontal line denoted the detection limit of VRE in fecal
samples by broth enrichment ~ 200 cfu/g (2.3 log10 cfu/g).
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http://www.biomedcentral.com/1471-2334/14/514hepatocellular carcinoma on 31 July 2012. He developed
recurrent ascites as a result of portal vein and hepatic vein
stenosis 6 months post-transplant requiring multiple
episodes of hospitalization. On 26 February 2014, he was
detected to have gastrointestinal colonization of VRE and
was subjected to VRE decolonization after 13 days of
hospitalization (Figure 2). However, patient had poor tol-
erance to oral ingestion of polyethylene glycol for bowel
preparation due to refractory ascites. Since the procedure
of decolonization was started, it was continued despite in-
sufficient bowel preparation. Patient had transient sup-
pression of VRE between day 14 and 19 and VRE relapsed
on day 27 of hospitalization. The decolonization regimen
was not successful in this case with inadequate bowel
preparation.
Case 3: A 44-year-old man was transferred from a re-
gional hospital to the Liver Transplant Unit of Queen
Mary Hospital for consideration of cadaveric liver trans-
plantation due to hepatitis B-related hepatic failure on
15 March 2014. He was found to have gastrointestinal
carriage of VRE upon admission screening. While wai-
ting for a potential liver graft, VRE decolonization wasinitiated on day 5 of hospitalization. He remained VRE
negative on serial monitoring till day 62 of hospitalization
despite intermittent use of antibiotics (Figure 3).
Case 4: A 71-year-old-lady was transferred from a re-
gional hospital to the Cardiothoracic Surgical Unit, Queen
Mary Hospital, for consideration of surgical intervention
for viridans streptococci-related infective endocarditis
complicated with cardiac failure. She had history of chro-
nic rheumatic heart disease with mitral stenosis, mitral
regurgitation, aortic regurgitation, and tricuspid regurgita-
tion. She was noted to have gastrointestinal carriage of
VRE upon admission screening, and was put on VRE
decolonization as per protocol on day 10 of hospita-
lization. Serial rectal swabs culture remained VRE negative
(broth enrichment culture) till day 23 of hospitalization
(Figure 4). However, patient developed respiratory dis-
tress, metabolic acidosis, hypotension, oliguric renal im-
pairment, and radiological appearance of dilated bowel
loops suggestive of mesenteric ischemia on day 25. Urgent
exploratory laparotomy revealed the presence of 300 ml
foul-smelling, blood-stained peritoneal fluid with gan-
grenous change of bowel from duodenojejunal flexure to
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Figure 2 Serial quantitative culture of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium and concomitant use of
antimicrobial agents in case 2. Note. Intravenous piperacillin-tazobactam 4.5 gm iv q12h, daptomycin 250 mg iv q12h, and metronidazole
500 mg iv q8h were given from day 3 for empirical treatment of spontaneous bacterial peritonitis, while intravenous piperacillin-tazobactam 4.5 gm
iv q12h, and daptomycin 250 mg iv q12h were given between day 45 and 56 for clinical diagnosis of another episode of spontaneous bacterial
peritonitis. The dotted horizontal line denoted the detection limit of VRE in fecal samples by broth enrichment ~ 200 cfu/g (2.3 log10 cfu/g).
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http://www.biomedcentral.com/1471-2334/14/514mid-sigmoid colon. Despite empirical use of meropenem
and daptomycin, inotropic and ventilator support, patient
succumbed on day 26 of hospitalization. No VRE could be
detected in all her clinical specimens or serial rectal swabs
after decolonization.1 2 3 10 11 2021 22 23 2
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Figure 4 Serial quantitative culture of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium and concomitant use of
antimicrobial agents in case 4. Note. Intravenous ampicillin 2 gm iv q8h, and gentamicin 40 mg iv q8h were given from the referral hospital
for treatment of infective endocarditis due to viridans streptococci. Antibiotic was changed to benzyl penicillin 3 MU iv q4h on day 7 upon
clinical consultation to microbiologist, and stopped on day 17 of hospitalization after completion of treatment. Meropenem 500 mg iv q12h and
one dose of daptomycin 350 mg iv was given on day 25 for systemic sepsis complicating mesenteric ischemia and bowel gangrene. Patient
succumbed on day 26 of hospitalization despite maximal supportive therapy. The dotted horizontal line denoted the detection limit of VRE in
fecal samples by broth enrichment ~ 200 cfu/g (2.3 log10 cfu/g).
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http://www.biomedcentral.com/1471-2334/14/514Vitek 2 automated identification system (bioMerieux,
France) as previously described [4]. The Kirby-Bauer
disk diffusion method and E-test (AB Biodisk, Solna,
Sweden) were used to determine the antimicrobial sus-
ceptibility of the enterococci. Isolates with potential
vancomycin resistance were proceeded to vanA gene
PCR and MLST as previously described [4]. For VRE
bacterial load quantitation, around 1 g of fecal sample
was suspended into 2 ml normal saline and serially di-
luted suspensions were plated onto chromogenic agar.
In addition, broth enrichment was performed by inocu-
lating another 10 μl aliquot of the fecal suspension into
the vancomycin containing brain-heart-infusion broth.
The broth was incubated at 37°C overnight and further
subcultured onto chromogenic agar in 35°C aerobic in-
cubation for 48 hours. The lower detection limit of this
method is 200 cfu/g.
Discussion
Decolonization of VRE poses a great challenge for cli-
nical microbiologists and infection control professionals.
It is difficult to suppress the fecal burden of enterococci,
ranging from 1–10 million cfu/g of stool, within the
gastrointestinal tract by sole use of antimicrobial agents
that are only bacteriostatic. We aim to overcome the
problem of significant enterococci burden by mechanical
removal of fecal load before the administration of high
concentration of topical antimicrobial agents. Therefore,in addition to systemic and topical antibiotics, we adopt
a protocol for bowel wash-out commonly used prior to
colonoscopy to remove the majority of the fecal bacterial
burden, and combined it with adjunctive infection con-
trol measures and probiotic. To our knowledge, the use
of polyethylene glycol for bowel preparation in the aim
to eliminate fecal bacterial population has not been
attempted in previous eradication protocols for VRE or
other multiple drug resistant bacteria. We have success-
fully eradicated VRE carriage in a high-risk patient with
end-stage cirrhosis before cadaveric liver transplantation.
This patient was chosen as the first case in our pilot
study because decolonization of VRE is crucial in liver
transplant candidates. In one study, it was found that
liver transplant candidates and recipients with VRE
colonization had an increased risk of VRE infection
(adjusted odd ratio 3.61, 95% CI 2.01-6.47) and of death
(adjusted odd ratio 2.12, 95% CI 1.27-3.54) compared
with non-colonized patients [5].
In the literature, antimicrobial agents with high luminal
concentration had been used to decolonize gastrointes-
tinal carriage of VRE in 142 patients (Table 2). Bacitracin-
containing regimens given orally or via gastrostomy tube
for 10 days to 29 days were most common, and was used
in 76 (54%) of 142 patients [7-12]. The results were rather
variable, while the overall observed rate of VRE clearance
was found to be 43% to 100% in patients treated with
bacitracin-containing regimens [7,9,11], long term follow
Table 2 Summary of gastrointestinal decolonization of vancomycin-resistant Enterococcus by antimicrobial therapy
Ref Country/year of
publication/study setting
Decolonization regimens/
study end point
(if mentioned)
Results at study end point Microbiology culture
methods/presence of broth
enrichment or not
[7] US/1994/observational study Oral vancomycin 125 mg q6h
for 10 daysa/follow up for
15 days post treatment
VRE negative in 8 (42%) of
19 patients
Campylobacter agar
containing 10 μg/ml of
vancomycin (B-D
Microbiology Systems,
Cockeysville, MD, USA)/no
broth enrichment
[7] US/1994/observational study Oral bacitracin 25,000 U
(500 mg) q6h for 10 days/
follow up for 15 days post
treatment
VRE negative in 8 (100%) of
8 patients
Campylobacter agar
containing 10 μg/ml of
vancomycin (B-D
Microbiology Systems,
Cockeysville, MD, USA)/no
broth enrichment
[15] US/1995/observational study Oral novobiocin (500 mg q6h
plus oral tetracycline 500 mg
q6h (five patients) or
intravenous doxycycline
100 mg q12h (one patient)
for a median of 3.5 days
(range, 1 to 6 days)
VRE negative in only one
patient while receiving
decolonization therapy
Not mentioned
[8] US/1995/observational study Bacitracin 25,000 U (diluted in
5 mL of 0.9% normal saline)
given orally or by
gastrostomy tube twice a day
for 10 days/follow up for
3 weeks post treatment
VRE negative in 5 (63%) of
8 patients
Not mentioned
[9] Canada/1999/prospective
observational cohort study in
a tertiary care institution
Oral doses of bacitracin
solution (75,000 U/15 mL)
four times daily and
doxycycline 100 mg once
daily for 14 days/follow up
for 4 months
VRE negative in 15 (100%) of
the antibiotic treated vs 8
(33.3%) of the untreated
patients (P <0 .001) at the
end of treatment; but VRE
positive in 9 (60%) of 15 and
15 (62.5%) of 24 in the
treated and untreated cohort
(p = 0.86) following up for a
mean of 127 and 130 days
respectively b
M-enterococcal agar with
vancomycin (6 mg/mL)/no
broth enrichment
[10] US/2001/randomized,
controlled study
Oral zinc bacitracin (50,000 U)
q6h for 10 days vs placebo/
follow up for 3 weeks post
treatment
VRE negative in 2 (33%) of
6 patients in each group after
3 weeks post treatment
Bile esculin agar plates
supplemented with 6 mg/mL
of vancomycin/no broth
enrichment
[14] US/2001/phase II,
double-blinded,
randomized, multicenter,
placebo-controlled study
Oral ramoplanin: 2 daily
doses of 100 mg or 400 mg
or placebo for 7 days/follow
up on day 0, 7, and 14 post
treatment
Day 0: VRE negative in 17
(81%) of 21 and 18 (90%) of
20 patients in the 100-mg
and 400-mg ramoplanin
groups; Day 7: VRE negative
in 6 (29%) of 21 and 7 (41%)
of 17 in the 100-mg and
400-mg ramoplanin groups;
Day 14: VRE negative in 4
(21%) of 19 and 5 (29%) of
17 patients in the 100-mg
and 400-mg ramoplanin
groupsc
Bile-esculin azide broth that
contained 6 mg/mL of
vancomycin (Hardy
Diagnostics)/broth
enrichment
[12] US/2002/observational study Oral bacitracin (25,000 U
three times daily) and oral
gentamicin (80 mg three
times daily) for a mean
duration of 16 days (median,
14 days; range, 7 to 29 days)/
follow up for 3 months post
treatment
VRE negative in 5 (17.8%) of
28 patients
Not mentioned
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Table 2 Summary of gastrointestinal decolonization of vancomycin-resistant Enterococcus by antimicrobial therapy
(Continued)
[11] France/2010/observational
study in a geriatric
rehabilitation care facility
Oral bacitracin 30,000 U three
times daily for 15 days/follow
up for 6 months
VRE negative in 3 (43%) of 7
patients at the end of
therapy and at 6 months
Not mentioned
[11] France/2010/observational
study in a geriatric
rehabilitation care facility
Bacitracin 30,000 U three
times daily plus streptomycin
1 g once daily orally for
15 days/follow up for
6 months
VRE negative in 3 (75%) of 4
patients at the end of
therapy and at 6 months
Not mentioned
Note. U, units; VRE, vancomycin-resistant enterococci; ahigh intraluminal concentrations attained with oral vancomycin administration greatly exceed the MICs of
VRE; bQuantitative VRE stool cultures in the treated cohort revealed an initial 3.1 log10/g decrease, but there was an increase to pretreatment levels of 7.8 and 7.4
log10/g at 2–4 and 5–7 weeks post-treatment respectively;
cFor placebo group, VRE negative in none of 20 patients in day 0, 2 (10%) of 20 patients in day 7, and 5
(25%) of 20 patients in day 14 post treatment.
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53% at 3 weeks post-treatment [8,10]. In one study using a
combination of oral bacitracin and doxycycline as VRE
eradication regimen, although quantitation of VRE in stool
showed an initial 3-log reduction of VRE count per gram
of stool during the 2-week therapy, the VRE count in stool
increased to pretreatment levels of 7.8 and 7.4 log10/g at
2–4 and 5–7 weeks post-treatment respectively [9]. In
another randomized placebo controlled study to assess
the use of 10-day course of zinc bacitracin capsules in
enteric eradication of VRE, only 2 (33%) of 6 patients in
each group were VRE negative after 3 weeks suggesting
that there was no difference in eradication rate of VRE in
the zinc bacitracin and the control group [10]. In a later
study, combination of oral bacitracin and gentamicin was
evaluated. After 3 months of follow up, only 5 (18%) of 28
patients had no VRE isolated from stool cultures. Anti-
microbial side effects were a major concern. Of the 45 pa-
tients originally enrolled on the treatment arm, 17 (38%)
could not tolerate bacitracin and gentamicin because of
nausea, vomiting, and diarrhea [12]. Ramoplanin, an orally
administered lipoglycodepsipeptide antibiotic that is not
absorbed systemically, has in vitro activity against vanco-
mycin-resistant E. faecium and E. faecalis, and has been
shown to suppress gastrointestinal colonization of VRE in
up to 90% of patients during the course of ramoplanin
in a phase II, double-blinded, randomized, multicenter,
placebo-controlled study. However, recurrence of VRE
colonization was observed in most patients 14 days after
treatment [13,14]. Short courses of novobiocin in com-
bination with tetracycline or doxycycline were also inef-
fective in eradicating gastrointestinal carriage of VRE [15].
With reference to the suboptimal VRE eradication out-
comes in the literature when antimicrobial treatment
was used alone without fecal wash-out, we attempted to
reduce the microbial burden of the gastrointestinal tract
by performing bowel wash-out prior to antimicrobial
treatment. In addition, we used a new combination of a
5-day course of oral linezolid with systemic effect and
oral non-absorbable daptomycin with topical effect to
maximize the anti-VRE activity in the gastrointestinaltract. Daptomycin oral therapy had previously been given
with minimal systemic absorption [16]. Oral absorbable
linezolid may help to decrease VRE counts in biliary or
urinary system, but even systemic antibiotics may not
work if patients have stone or parasitic nidus in the biliary
or urinary tract associated with biofilm formation which
can be colonized by VRE. Thus organ imaging to exclude
these kinds of foci would be important before instituting
the decolonization. This regimen successfully reduced the
quantitative bacterial count of VRE from 104 - 105 cfu/g of
stool to undetectable level within 3 days of decolonization
therapy in at least 3 patients (case 1, case 3, and case 4).
However, our regimen failed in one patient (case 2) who
could not tolerate oral ingestion of polyethylene glycol for
bowel preparation due to refractory ascites. We believe
that complete fecal wash-out is the key component of our
VRE decolonization regimen.
Adjunctive infection control measures are essential to
prevent re-acquisition of VRE from patients’ skin and hos-
pital environment during the process of decolonization.
Preparation of 4% chlorhexidine gluconate bath and
shampoo was used to reduce the cutaneous colonization
of VRE as previously described [17]. Thorough environ-
mental disinfection by sodium hypochlorite 1,000 ppm
was done twice daily. At the time of bathing, the patient’s
clothes, underwear, and bed linens were replaced and sent
for hot laundry daily. Probiotic Lactobacillus rhamnosus
GG 80 mg daily for repopulating the gram positive anaer-
obic flora was used after the 5-day course of linezolid and
daptomycin to consolidate the effect of decolonization
and may improve the colonization resistance against re-
colonization by VRE. In fact, use of Lactobacillus rham-
nosus GG or Lactobacillus rhamnosus Lcr35 had been
attempted to decolonize 49 patients in the literature
with variable results (Table 3). A randomized placebo-
controlled study using standard dose of Lactobacillus for
3 weeks in children showed that rectal swab was rendered
negative for VRE at the end of therapy in 63% of patients
using semi-quantitative method without broth enrich-
ment, but the difference in VRE carrier state was no lon-
ger significant 1 week after completion of treatment [18],
Table 3 Summary of gastrointestinal decolonization of vancomycin-resistant enterococci by probiotic therapy
Ref Country/year of
publication/study setting
Decolonization regimens/
study end point
(if mentioned)
Results at study end point Microbiology culture
methods/presence of broth
enrichment or not
[20] Australia/2007/double-blind,
randomized, placebo-
controlled trial in nephrology
patients
Lactobacillus rhamnosus GG
in the form of commercially
available yoghurt: 100 g daily
of yoghurt containing
Lactobacillus rhamnosus GG
for 4 weeks/follow up for
4 weeks post treatment
VRE negative in all 11
patients in treatment group
at the end of therapy; 8
(73%) remained VRE negative
4 weeks post treatment; VRE
negative in 1 (8%) of 12
control patient at the end of
treatment
Enterococcosel agar (BD,
Sparks, Md, USA) containing
6 μg vancomycin/no broth
enrichment
[21] France/2010/double-blind
randomized pilot study in
adult
Lactobacillus rhamnosus
Lcr35: 5-week course of Lcr35
(109 active cells daily) or a
placebo/follow up till the
end of therapy
VRE negative in 3 (50%) of 6
patients in treatment group
vs 2 (100%) of 2 patients in
control group at the end of
therapy
Not mentioned
[18] Poland/2011/randomized,
single-blind, placebo-
controlled study in children
Lactobacillus rhamnosus GG 3
billion colony forming unit
per day vs placebo for
21 days/follow up till the end
of therapy
VRE negative in 20 (63%) of
32 patients in treatment
group vs 7 (24%) of 29 in
control group (p = 0.002)
Selective medium
(D-Coccosel agar,
BioMe’rieux) and a
chromogenic medium
(ChromID, BioMe’rieux)/no
broth enrichment
Note: VRE, vancomycin-resistant enterococci.
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temporary. Furthermore, using probiotic containing Lacto-
bacillus species alone may not be feasible in patient recei-
ving antibiotics [19]. In contrast, with the appropriate use
of fecal wash-out, antimicrobial agents, and Lactobacillus
rhamnosus GG, our patients appeared to maintain a per-
sistent VRE negative status, tested by broth enrichment
culture of fecal samples, despite the use of broad-spectrum
antibiotics after the decolonization.
The major limitation in this study is that the expe-
rience with our decolonization regimen was restricted to
four patients to date. Additionally, there are potential
risks and discomfort associated with the use of po-
lyethylene glycol for fecal wash-out. Patients with severe
renal impairment may have a risk of fluid retention and
electrolyte disturbance. Patients with refractory ascites
may not be able to tolerate the volume of polyethylene
glycol. Inadequate bowel preparation may subsequently
result in failure of VRE decolonization, like case 2 in our
series. Further clinical trials should be performed to
validate the effectiveness of this regimen and assess the
potential development of antimicrobial resistance, as
linezolid and daptomycin will be increasingly used in
hospitals with rising incidence of infections due to re-
sistant organisms [22,23]. Stool concentration of oral
linezolid and daptomycin can be done to compare against
the measured MICs of the VRE isolates. However, we be-
lieve that the findings in this study are significant, where
high-risk patient (case 1) with critical underlying co-
morbidities has remained VRE negative for over 100 days
after decolonization, even with subsequent use of broad-
spectrum antibiotic therapy. Cost-effective analysis should
be conducted in subsequent studies to measure theexpenditure in VRE decolonization and medical manage-
ment of invasive VRE infections. In addition, VRE
decolonization on an outpatient basis, such as patient’s
own residence, may be explored, especially in resource-
poor regions where prolonged hospitalization for the pur-
pose of decolonization may not be feasible.Conclusion
Our experience revealed that sustained decolonization of
gastrointestinal carriage of VRE was possible by a combin-
ation of environmental disinfection, patient isolation, bowel
preparation to wash-out the fecal bacterial population
using polyethylene glycol, a five-day course of oral absorb-
able linezolid and non-absorbable daptomycin to suppress
any remaining VRE, and subsequent oral Lactobacillus
rhamnosus GG to maintain the colonization resistance.
This strategy should be further studied in settings of low
VRE endemicity with limited isolation facilities.Consent
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